Exchange Rate
This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1380, the reference rate of the European Central Bank on June 30, 2019.
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the second quarter of 2019 on Tuesday, August 6, 2019, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Wilfried Vancraen, Founder and Chief Executive Officer; Peter Leys, Executive Chairman; and Johan Albrecht, Chief Financial Officer. A question-and-answer session will follow management’s remarks.
- To access the conference call, please dial 844-469-2530 (U.S.) or 765-507-2679 (international), passcode #6466129.
The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website for one year.
About Materialise
Materialise incorporates nearly 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, current estimates of fiscal 2019 revenues, deferred revenue from annual licenses and maintenance and Adjusted EBITDA, the timing, benefits and impact on our fiscal 2019 results of the Engimplan investment, results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including our strategic priorities for 2019), and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release.
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statements (Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
|
|
|
For the six months ended June 30, |
|
||||||||||||||
In 000 |
|
2019 |
|
|
2019 |
|
|
2018 |
|
|
|
|
|
2019 |
|
|
2018 |
|
|||||
|
|
U.S.$ |
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Revenue |
|
|
55,084 |
|
|
|
48,404 |
|
|
|
45,076 |
|
|
|
|
|
|
95,519 |
|
|
|
88,975 |
|
Cost of sales |
|
|
(24,896) |
|
|
|
(21,877) |
|
|
|
(20,288) |
|
|
|
|
|
|
(43,413) |
|
|
|
(40,232) |
|
Gross profit |
|
|
30,188 |
|
|
|
26,527 |
|
|
|
24,788 |
|
|
|
|
|
|
52,106 |
|
|
|
48,743 |
|
Gross profit as % of revenue |
|
|
54,8% |
|
|
|
54,8% |
|
|
|
55,0% |
|
|
|
|
|
|
54,6% |
|
|
|
54.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
|
(6,941) |
|
|
|
(6,100) |
|
|
|
(5,831) |
|
|
|
|
|
|
(11,786) |
|
|
|
(11,446) |
|
Sales and marketing expenses |
|
|
(14,991) |
|
|
|
(13,173) |
|
|
|
(11,843) |
|
|
|
|
|
|
(25,252) |
|
|
|
(22,441) |
|
General and administrative expenses |
|
|
(9,773) |
|
|
|
(8,588) |
|
|
|
(8,026) |
|
|
|
|
|
|
(16,184) |
|
|
|
(15,187) |
|
Net other operating income (expenses) |
|
|
1,559 |
|
|
|
1,370 |
|
|
|
1,840 |
|
|
|
|
|
|
2,627 |
|
|
|
2,390 |
|
Operating (loss) profit |
|
|
40 |
|
|
|
36 |
|
|
|
928 |
|
|
|
|
|
|
1,511 |
|
|
|
2,059 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial expenses |
|
|
(356) |
|
|
|
(313) |
|
|
|
(404) |
|
|
|
|
|
|
(1,509) |
|
|
|
(2,516) |
|
Financial income |
|
|
140 |
|
|
|
123 |
|
|
|
29 |
|
|
|
|
|
|
728 |
|
|
|
1,431 |
|
Share in loss of joint venture |
|
|
(93) |
|
|
|
(82) |
|
|
|
(141) |
|
|
|
|
|
|
(205) |
|
|
|
(244) |
|
(Loss) profit before taxes |
|
|
(268) |
|
|
|
(236) |
|
|
|
411 |
|
|
|
|
|
|
524 |
|
|
|
729 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
(69) |
|
|
|
(61) |
|
|
|
(42) |
|
|
|
|
|
|
(1,126) |
|
|
|
(543) |
|
Net (loss) profit for the period |
|
|
(338) |
|
|
|
(297) |
|
|
|
369 |
|
|
|
|
|
|
(601) |
|
|
|
186 |
|
Net (loss) profit attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The owners of the parent |
|
|
(338) |
|
|
|
(297) |
|
|
|
369 |
|
|
|
|
|
|
(601) |
|
|
|
186 |
|
Non-controlling interest |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share attributable to owners of the parent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Basic |
|
|
(0.01) |
|
|
|
(0.01) |
|
|
|
0.01 |
|
|
|
|
|
|
(0.01) |
|
|
|
0.00 |
|
Diluted |
|
|
(0.01) |
|
|
|
(0.01) |
|
|
|
0.01 |
|
|
|
|
|
|
(0.01) |
|
|
|
0.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average basic shares outstanding |
|
|
52,891 |
|
|
|
52,891 |
|
|
|
47,428 |
|
|
|
|
|
|
52,891 |
|
|
|
47,428 |
|
Weighted average diluted shares outstanding |
|
|
52,891 |
|
|
|
52,891 |
|
|
|
47,428 |
|
|
|
|
|
|
52,891 |
|
|
|
47,428 |
|
Consolidated statements of comprehensive income (Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
|
|
|
For the six months ended June 30, |
|
||||||||||||||
In 000 |
|
2019 |
|
|
2019 |
|
|
2018 |
|
|
|
|
|
2019 |
|
|
2018 |
|
|||||
|
|
U.S.$ |
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net profit (loss) for the period |
|
|
(338) |
|
|
|
(297) |
|
|
|
369 |
|
|
|
|
|
|
(602) |
|
|
|
186 |
|
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange difference on translation of foreign operations |
|
|
(489) |
|
|
|
(430) |
|
|
|
53 |
|
|
|
|
|
|
157 |
|
|
|
(42) |
|
Other comprehensive income (loss), net of taxes |
|
|
(489) |
|
|
|
(430) |
|
|
|
53 |
|
|
|
|
|
|
157 |
|
|
|
(42) |
|
Total comprehensive income (loss) for the year, net of taxes |
|
|
(827) |
|
|
|
(727) |
|
|
|
422 |
|
|
|
|
|
|
(445) |
|
|
|
144 |
|
Total comprehensive income (loss) attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The owners of the parent |
|
|
(827) |
|
|
|
(727) |
|
|
|
422 |
|
|
|
|
|
|
(445) |
|
|
|
144 |
|
Non-controlling interest |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
– |
|
|
|
– |
|
Consolidated statement of financial position (Unaudited) |
|
|
|
|
|
|
|
|
|
|
As of June 30, |
|
|
As of December 31, |
|
||
In 000 |
|
2019 |
|
|
2018 |
|
||
|
|
€ |
|
|
€ |
|
||
Assets |
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-current assets |
|
|
|
|
|
|
|
|
Goodwill |
|
|
17,491 |
|
|
|
17,491 |
|
Intangible assets |
|
|
25,828 |
|
|
|
26,326 |
|
Property, plant & equipment |
|
|
97,159 |
|
|
|
92,537 |
|
Investments in joint ventures |
|
|
|
|
|
|
|
|
Deferred tax assets |
|
|
260 |
|
|
|
315 |
|
Other non-current assets |
|
|
10,080 |
|
|
|
7,237 |
|
Total non-current assets |
|
|
150,819 |
|
|
|
143,906 |
|
|
|
|
||||||
Current assets |
|
|
|
|
|
|
|
|
Inventories |
|
|
10,031 |
|
|
|
9,986 |
|
Trade receivables |
|
|
40,073 |
|
|
|
36,891 |
|
Other current assets |
|
|
7,746 |
|
|
|
6,936 |
|
Cash and cash equivalents |
|
|
108,865 |
|
|
|
115,506 |
|
Total current assets |
|
|
166,715 |
|
|
|
169,319 |
|
Total assets |
|
|
317,534 |
|
|
|
313,225 |
|
|
|
As of June 30, |
|
|
As of December 31, |
|
||
In 000 |
|
2019 |
|
|
2018 |
|
||
|
|
€ |
|
|
€ |
|
||
Equity and liabilities |
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
Share capital |
|
|
3,050 |
|
|
|
3,050 |
|
Share premium |
|
|
136,869 |
|
|
|
136,637 |
|
Consolidated reserves |
|
|
(2,447) |
|
|
|
(1,848) |
|
Other comprehensive income |
|
|
(1,692) |
|
|
|
(1,850) |
|
Equity attributable to the owners of the parent |
|
|
135,781 |
|
|
|
135,989 |
|
Non-controlling interest |
|
|
– |
|
|
|
– |
|
Total equity |
|
|
135,781 |
|
|
|
135,989 |
|
|
|
|
||||||
Non-current liabilities |
|
|
|
|
|
|
|
|
Loans & borrowings |
|
|
91,884 |
|
|
|
92,440 |
|
Deferred tax liabilities |
|
|
5,979 |
|
|
|
6,226 |
|
Deferred income |
|
|
5,282 |
|
|
|
4,587 |
|
Other non-current liabilities |
|
|
886 |
|
|
|
868 |
|
Total non-current liabilities |
|
|
104,031 |
|
|
|
104,121 |
|
|
|
|
||||||
Current liabilities |
|
|
|
|
|
|
|
|
Loans & borrowings |
|
|
15,814 |
|
|
|
13,598 |
|
Trade payables |
|
|
17,902 |
|
|
|
18,667 |
|
Tax payables |
|
|
2,358 |
|
|
|
2,313 |
|
Deferred income |
|
|
24,776 |
|
|
|
23,195 |
|
Other current liabilities |
|
|
16,873 |
|
|
|
15,342 |
|
|
|
|
||||||
Total current liabilities |
|
|
77,722 |
|
|
|
73,115 |
|
Total equity and liabilities |
|
|
317,534 |
|
|
|
313,225 |
|
Consolidated statement of cash flows (Unaudited) |
|
|
|
|
|
|
For the six months ended June 30, |
||
in 000 |
|
2019 |
|
2018 |
|
|
€ |
|
€ |
Operating activities |
|
|
|
|
Net (loss) profit for the period |
|
(602) |
|
186 |
Non-cash and operational adjustments |
|
|
|
|
Depreciation of property, plant & equipment |
|
6,950 |
|
5,517 |
Amortization of intangible assets |
|
2,229 |
|
2,498 |
Share-based payment expense |
|
197 |
|
366 |
Loss (gain) on disposal of property, plant & equipment |
|
134 |
|
(90) |
Movement in provisions |
|
20 |
|
- |
Movement reserve for bad debt |
|
(116) |
|
68 |
Financial income |
|
(171) |
|
(58) |
Financial expense |
|
1,232 |
|
1,032 |
Impact of foreign currencies |
|
(288) |
|
111 |
Share in loss of a joint venture (equity method) |
|
205 |
|
244 |
(Deferred) income taxes |
|
1,126 |
|
543 |
Other |
|
(196) |
|
(164) |
Working capital adjustment & income tax paid |
|
|
|
|
Increase in trade receivables and other receivables |
|
(4,466) |
|
(4,147) |
Decrease (increase) in inventories |
|
(43) |
|
774 |
Increase in trade payables and other payables |
|
3,737 |
|
5,230 |
Income tax paid |
|
(1,108) |
|
(1,555) |
Net cash flow from operating activities |
|
8,840 |
|
11,031 |
|
|
|
|
|
|
|
For the six months ended June 30, |
||
in 000 |
|
2019 |
|
2018 |
|
|
€ |
|
€ |
Investing activities |
|
|
|
|
Purchase of property, plant & equipment |
|
(4,827) |
|
(8,588) |
Purchase of intangible assets |
|
(1,457) |
|
(583) |
Proceeds from the sale of property, plant & equipment & intangible assets (net) |
|
(3) |
|
436 |
Convertible loan to third party |
|
(2,500) |
|
– |
Investments in joint-ventures |
|
– |
|
– |
Interest received |
|
– |
|
(2) |
Net cash flow used in investing activities |
|
(8,787) |
|
(8,737) |
|
|
|
|
|
Financing activities |
|
|
|
|
Proceeds from loans & borrowings |
|
3,000 |
|
18,770 |
Repayment of loans & borrowings |
|
(5,818) |
|
(14,074) |
Repayment of finance leases |
|
(2,765) |
|
(1,366) |
Capital increase |
|
– |
|
207 |
Interest paid |
|
(934) |
|
(814) |
Other financial income (expense) |
|
(292) |
|
(130) |
Net cash flow from (used in) financing activities |
|
(6,809) |
|
2,593 |
|
|
|
|
|
Net increase of cash & cash equivalents |
|
(6,756) |
|
4,887 |
Cash & cash equivalents at beginning of the year |
|
115,506 |
|
43,175 |
Exchange rate differences on cash & cash equivalents |
|
115 |
|
657 |
Cash & cash equivalents at end of the year |
|
108,865 |
|
48,719 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) |
||||||||||||||||||||
|
|
For the three months ended June 30, |
|
|
|
|
|
For the six months ended June 30, |
|
|||||||||||
In 000 |
|
2019 |
|
|
2018 |
|
|
|
|
|
2019 |
|
|
2018 |
|
|||||
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net profit (loss) for the period |
|
|
(297) |
|
|
|
369 |
|
|
|
|
|
|
|
(601) |
|
|
|
186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
61 |
|
|
|
42 |
|
|
|
|
|
|
|
1,126 |
|
|
|
543 |
|
Financial expenses |
|
|
313 |
|
|
|
404 |
|
|
|
|
|
|
|
1,509 |
|
|
|
2,516 |
|
Financial income |
|
|
(123 |
) |
|
|
(29 |
) |
|
|
|
|
|
|
(728) |
|
|
|
(1,431) |
|
Share in loss of joint venture |
|
|
82 |
|
|
|
141 |
|
|
|
|
|
|
|
205 |
|
|
|
244 |
|
Depreciation and amortization |
|
|
4,649 |
|
|
|
4,009 |
|
|
|
|
|
|
|
9,178 |
|
|
|
8,538 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
|
4,685 |
|
|
|
4.940 |
|
|
|
|
|
|
|
10,691 |
|
|
|
10,074 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash stock-based compensation expense (1) |
|
|
(374) |
|
|
|
(276 |
) |
|
|
|
|
|
|
(196) |
|
|
|
(366) |
|
Acquisition-related expenses business combinations |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED EBITDA |
|
|
5,059 |
|
|
|
5,216 |
|
|
|
|
|
|
|
10,888 |
|
|
|
10,440 |
|
(1) | Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees. |
Segment P&L (Unaudited) |
||||||||||||
In 000 |
|
Materialise Software |
|
Materialise Medical |
|
Materialise Manu- facturing |
|
Total segments |
|
Unallocated (1)(2) |
|
Consoli- Dated |
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
|
For the three months ended June 30, 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
9,320 |
|
14,546 |
|
24,550 |
|
48,415 |
|
(11) |
|
48,404 |
Segment EBITDA |
|
2,055 |
|
2,738 |
|
2,835 |
|
7,629 |
|
(2,571) |
|
5,059 |
|
|
|
|
|
|
|
||||||
Segment EBITDA % |
|
22.1% |
|
18.8% |
|
11.5% |
|
15.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
9,131 |
|
12,400 |
|
23,387 |
|
44,918 |
|
158 |
|
45,076 |
Segment EBITDA |
|
2,859 |
|
2,124 |
|
2,264 |
|
7,247 |
|
(2,031) |
|
5,216 |
|
|
|
|
|
|
|
||||||
Segment EBITDA % |
|
31.3% |
|
17.1% |
|
9.7% |
|
16.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In 000 |
|
Materialise Software |
|
Materialise Medical |
|
Materialise
Manu-
|
|
Total segments |
|
Unallocated (1)(2) |
|
Consoli- Dated |
|
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
|
€ |
For the six months ended June 30, 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
18,670 |
|
28,112 |
|
48,734 |
|
95,515 |
|
4 |
|
95,519 |
Segment EBITDA |
|
5,016 |
|
4,511 |
|
6,530 |
|
16,058 |
|
(5,170) |
|
10,888 |
|
|
|
|
|
|
|
||||||
Segment EBITDA % |
|
22.1% |
|
16.0% |
|
13.4% |
|
16.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30, 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
17,457 |
|
24,346 |
|
47,019 |
|
88,822 |
|
153 |
|
88,975 |
Segment EBITDA |
|
5,183 |
|
4,184 |
|
5,397 |
|
14,764 |
|
(4,324) |
|
10,440 |
|
|
|
|
|
|
|
||||||
Segment EBITDA % |
|
29.7% |
|
17.2% |
|
11.5% |
|
16.6% |
|
|
|
|
(1) |
Unallocated Revenues consist of occasional one-off sales in our core competencies not allocated to any of our segments. Unallocated Segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense). | |
(2) |
Unallocated Segment EBITDA consists of the added non-cash stock-based compensation expenses that are included in Adjusted EBITDA. |
Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
|
|
|
For the six months ended June 30, |
|
||||||||||||
In 000 |
|
2019 |
|
|
2018 |
|
|
|
|
|
2019 |
|
|
2018 |
|
||||||
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net profit (loss) for the period |
|
|
(297) |
|
|
|
369 |
|
|
|
|
|
|
|
(601) |
|
|
|
186 |
|
|
Income taxes |
|
|
61 |
|
|
|
42 |
|
|
|
|
|
|
|
1,126 |
|
|
|
543 |
|
|
Financial cost |
|
|
313 |
|
|
|
404 |
|
|
|
|
|
|
|
1,509 |
|
|
|
2,516 |
|
|
Financial income |
|
|
(123) |
|
|
|
(29) |
|
|
|
|
|
|
|
(728) |
|
|
|
(1,431) |
|
|
Share in loss of joint venture |
|
|
82 |
|
|
|
141 |
|
|
|
|
|
|
|
205 |
|
|
|
244 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
|
36 |
|
|
|
928 |
|
|
|
|
|
|
|
1,511 |
|
|
|
2,059 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
4,649 |
|
|
|
4,009 |
|
|
|
|
|
|
|
9,178 |
|
|
|
8,015 |
|
|
Corporate research and development |
|
|
502 |
|
|
|
527 |
|
|
|
|
|
|
|
1,014 |
|
|
|
1,044 |
|
|
Corporate headquarter costs |
|
|
3,108 |
|
|
|
3,235 |
|
|
|
|
|
|
|
5,777 |
|
|
|
5,700 |
|
|
Other operating income (expense) |
|
|
(501) |
|
|
|
(1,001) |
|
|
|
|
|
|
|
(1,107) |
|
|
|
(1,373) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment EBITDA |
|
|
7,629 |
|
|
|
7,247 |
|
|
|
|
|
|
|
16,058 |
|
|
|
14,764 |
|
|